Overview

A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg tested earlier in Phase II.

Phase:

Phase 2

Details

Lead Sponsor:

Shionogi

Collaborators:

Hormos Medical
QuatRx Pharmaceuticals

Treatments:

Tamoxifen